HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis-Reference-Cited by-同舟云学术

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis

Published:2023-11 Issue:11 Volume:10 Page:e733-e741
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Loosli Tom,Hossmann Stefanie,Ingle Suzanne M,Okhai Hajra,Kusejko Katharina,Mouton Johannes,Bellecave Pantxika,van Sighem Ard,Stecher Melanie,d'Arminio Monforte Antonella,Gill M John,Sabin Caroline A,Maartens Gary,Günthard Huldrych F,Sterne Jonathan A C,Lessells Richard,Egger Matthias,Kouyos Roger D

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference32 articles.

1. Update of recommendations on first- and second-line antiretroviral regimens,2019

2. End resistance to dolutegravir roll-out;Lancet HIV,2020

3. Genetic barrier to resistance for dolutegravir;Llibre;AIDS Rev,2015

4. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir;Cottrell;Clin Pharmacokinet,2013

5. Emergent resistance to dolutegravir among INSTI-naive patients on first-line or second-line antiretroviral therapy: a review of published cases;Cevik;Open Forum Infect Dis,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV drug resistance to integrase inhibitors in low- and middle-income countries;Nature Medicine;2024-01-23

2. Lenacapavir plus two bNAbs: feasible, with some caveats;The Lancet HIV;2024-01

3. A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings;Viruses;2023-12-14

4. Dolutegravir for second-line antiretroviral therapy: the beat goes on;The Lancet Global Health;2023-12

5. INSTI era resistance: emerging concern or marginal issue?;The Lancet HIV;2023-11